Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Ramucirumab Associated With OS Benefit in Aggressive NSCLC

October 17th 2017

Ramucirumab (Cyramza) plus docetaxel demonstrated an overall survival benefit versus placebo plus docetaxel in patients with advanced NSCLC whose disease rapidly progressed on first-line therapy,

Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC

October 16th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer (NSCLC).

Dr. Camidge on the ALTA Study of Brigatinib in NSCLC

October 16th 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the ALTA trial, which is exploring brigatinib (Alunbrig) in patients with ALK-positive non-small cell lung cancer.

Lower Dose Ceritinib With Food as Effective But Better Tolerated for ALK+ NSCLC

October 16th 2017

A lower dose of ceritinib taken with a low-fat meal showed similar efficacy with fewer dose reductions and less severe gastrointestinal adverse events versus a 750-mg dose taken without food for patients with untreated ALK-positive metastatic non–small cell lung cancer.

FISHing for a Better Assay in ALK-Positive Lung Cancer

October 16th 2017

In addition to proving the superiority of alectinib versus crizotinib, the phase III ALEX trial provided clear guidance on which of 2 assays evaluated could provide stronger guidance on which patients would respond to ALK-specific therapy.

IASLC Conference Will Highlight PACIFIC Trial QoL Data on Durvalumab

October 14th 2017

Fred R. Hirsch, MD, PhD, provides highlights of the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer, leading with his excitement for updated quality-of-life data from the PACIFIC trial of patients with locally advanced, unresectable stage III non–small cell lung cancer.

Frontline Alectinib Recommended for EU Approval for ALK+ NSCLC

October 14th 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of alectinib for the first-line treatment of adults with ALK-positive, advanced non–small cell lung cancer.

Immunotherapy Continues to Excite in NSCLC

October 13th 2017

Lawrence E. Feldman, MD, discusses first- and second-line therapy with checkpoint inhibitors in NSCLC, and the promise that emerging combinations could have on the field.

FDA Grants Priority Review to Afatinib for NSCLC With Rare EGFR Mutations

October 11th 2017

The FDA has granted a priority review to a supplemental new drug application for afatinib for the frontline treatment of patients with metastatic non-small cell lung cancer whose tumors harbor EGFR exon 21 (L861Q), G719X, or S768I substitution mutations.

No Survival Benefit With Abemaciclib in KRAS+ NSCLC

October 10th 2017

In topline results from the phase III JUNIPER trial, abemaciclib failed to meet its primary endpoint of improving overall survival versus erlotinib in patients with KRAS-mutated, advanced non–small cell lung cancer (NSCLC) who progressed after platinum-based chemotherapy.

Osimertinib Receives Breakthrough Therapy Designation for NSCLC in First-Line

October 9th 2017

The FDA has awarded Breakthrough Therapy Designation to osimertinib for first-line treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).

Dr. Hensing Discusses Studies in Stage III NSCLC

October 7th 2017

Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non-small cell lung cancer (NSCLC).

Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLC

October 7th 2017

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.

Advancing Stage III NSCLC Care Requires Personalized, Multidisciplinary Approach

October 5th 2017

Thomas A. Hensing, MD, discussed that modern technology and novel therapeutics must be managed by a multidisciplinary team to achieve optimal outcome for patients with stage III non-small cell lung cancer.

Dr. Villaflor Discusses Alectinib in ALK+ NSCLC

October 5th 2017

Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer.

Dr. Forster Discusses the ATLANTIS Study in Small-Cell Lung Cancer

October 5th 2017

Martin Forster, MD, medical oncologist, University College London Hospitals, discusses the ATLANTIS study in small-cell lung cancer.

Dr. Patel Discusses Checkpoint Blockade in NSCLC

October 5th 2017

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer.

Emerging Data Show Promise With Immunotherapy Combos in NSCLC

October 3rd 2017

Jyoti D. Patel, MD, discusses ongoing research investigating immunotherapy in combination with chemotherapy for patients with NSCLC.

Standard Biopsies Retain Significant Role in Lung Cancer Care

October 3rd 2017

Philip D. Bonomi, MD, discusses some of the known biomarkers in non-small cell lung cancer (NSCLC), the utilization of PD-L1, and other testing modalities.

Dr. Hensing on the Management of Stage III NSCLC

October 3rd 2017

Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses the management of patients with stage III non–small cell lung cancer (NSCLC).